3OCT

Gavi funds vaccines made in Africa

2 min read

13:42UTC

Gavi approved an extra $189 million for African vaccine manufacturing on 2 July, with $139 million to buy Africa-made vaccines and a first disbursement expected before year-end.

← Back to River boat carries Ebola 1,000 km downriver Jump to analysis ↓

ScienceDeveloping

Key takeaway

GAVI earmarked $139 million for Africa-made vaccines, its first direct funding to African manufacturers.

GAVI, the vaccine-financing alliance, approved an extra $189 million for the African Vaccine Manufacturing Accelerator (AVMA) at a board meeting that closed on Thursday 2 July, on top of the programme's existing $1 billion⁠¹. Of the new money, $139 million is earmarked to buy vaccines made in Africa, with the first cash expected to reach an African manufacturer in the second half of 2026, a first for the scheme. The board also set Gavi 6.0 targets for 2026 to 2030: reach 500 million more children and prevent an estimated 8 to 9 million deaths.

GAVI's approval landed the same fortnight the African Union pledged $910 million toward the Ebola response and Africa CDC won direct access to the World Bank-hosted Pandemic Fund, the continent assembling its own response money. An African plant still needs the technology transfer and sample access that the stalled PABS annex is meant to guarantee, so the money approved by GAVI and the deadlock in Geneva are two ends of one problem. Africa can now finance the plant; what it lacks is the legal right to make and keep what comes out of it.

Deep Analysis

In plain English

GAVI is a global vaccine-buying alliance that pools money from governments and donors to make vaccines cheaper and more available in lower-income countries. This $189 million top-up specifically backs vaccine factories being built in Africa, rather than paying to import vaccines made elsewhere, which is what usually happens today. Shorter supply chains mean less dependence on whichever country happens to have spare manufacturing capacity during the next outbreak. The money won't move immediately. GAVI expects the first payments to manufacturers in the second half of 2026, so this is a bet on future capacity rather than an immediate supply fix for the current Ebola outbreak.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: The African Union's 2021 target of manufacturing 60% of the continent's vaccines locally by 2040, adopted after COVID-19 exposed near-total import dependence, is the pledge AVMA's extra $189 million is meant to advance, with $139 million of it earmarked specifically for doses made on the continent rather than imported.

Counter-parallel: COVAX, the pooled procurement mechanism built for COVID-19, abandoned its own manufacturing-transfer ambitions by 2023 after spending most of its budget buying finished doses from Northern manufacturers instead of building African production lines, the outcome AVMA's structure is explicitly designed to avoid repeating.

Of GAVI's new $189 million, $139 million is ring-fenced for Africa-made vaccines specifically, on top of the programme's existing $1 billion; first disbursements are expected in the second half of 2026, meaning manufacturers will not see cash before this funding round translates into production contracts.

Structurally, AVMA is a supply-side subsidy: it pays manufacturers to build and hold capacity regardless of whether an order materialises. That contrasts with the US Biomedical Advanced Research and Development Authority's model, which pays through advance-purchase commitments tied to a specific pathogen and delivery date.

Supply-side funding like AVMA's builds capacity that can pivot across diseases; demand-side funding like BARDA's builds capacity faster for one named threat but leaves it idle once that threat passes.

Sources:Tech Times

Mentions:GAVI →Pandemic Fund →African Union →Africa CDC →Geneva →World Bank →CDC →African Vaccine Manufacturing Accelerator →

First Reported In

Update #9 · Ebola's toolkit arrives, outbreak climbs

Tech Times· 5 Jul 2026

Read original →

Causes and effects

Caused by

Africa CDC wins direct pandemic funding

The African Union's $910m Ebola pledge the same fortnight shows the continent assembling its own response and manufacturing money alongside Gavi's.

Occurred 17 Jun 2026

Read story →

This Event

Gavi funds vaccines made in Africa

Gavi's money lets Africa finance vaccine plants, though the sample and technology access to fill them still hinges on the stalled PABS annex.

Led to

PABS annex slips a fourth deadline

Gavi's manufacturing funding still lacks the annex guarantee the deferred PABS text was meant to provide.

Occurred 17 Jul 2026

Read story →

Different Perspectives

IGWG co-chair Tovar da Silva Nunes

The Brazilian co-chair closed the eighth pathogen-sharing session on 18 September without an agreed annex text, the second session in a row to end that way. He presented the outcome as continued commitment, with adoption due at the World Health Assembly in May 2027.

Fraport

The Frankfurt Airport operator has told staff to watch for fever, hessenschau reported, after six airport workers caught malaria. Germany does not require insecticide spraying of arriving aircraft cabins, and parasite genotyping to trace the source is due at the end of October.

European Centre for Disease Prevention and Control

ECDC reported the eight Frankfurt Airport malaria cases on 18 September and considers repeated arrivals of infected mosquitoes on aircraft likely. It has not ruled out local mosquitoes, and awaits genotyping due at the end of October.

Pan American Health Organization

PAHO counted 53,957 measles cases in the Americas by 19 September and is supporting Peru's response in Puno and Arequipa. It warns that October's Señor de los Milagros festivities and Pope Leo XIV's November visit could increase transmission.

Bangladesh Directorate General of Health Services

The DGHS recorded 1,030 measles-related deaths and 172,720 suspected cases by 14 September, after a campaign that reached 19.75 million children. Its disease-control director, Halimur Rashid, said further vaccination rounds were expected within two weeks.

Minapharm

The Egyptian drugmaker and its Berlin subsidiary ProBioGen were awarded up to US$16.5m by CEPI on 27 August to take a Bundibugyo vaccine into a Phase 1 trial in Africa. Final manufacture is planned for Cairo, making it CEPI's first Bundibugyo candidate with an African producer.